Article Versions Notes

Mueller RB, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019; 8(3):302. https://doi.org/10.3390/jcm8030302

Mueller, Ruediger B., Michael Spaeth, Cord von Restorff, Christoph Ackermann, Hendrik Schulze-Koops, and Johannes von Kempis. 2019. "Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol" Journal of Clinical Medicine 8, no. 3: 302. https://doi.org/10.3390/jcm8030302

Mueller, R. B., Spaeth, M., von Restorff, C., Ackermann, C., Schulze-Koops, H., & von Kempis, J. (2019). Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine, 8(3), 302. https://doi.org/10.3390/jcm8030302